Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRAT | O95237 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24804651 | 1.00 | LRAT (0.67) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL25733221 | 1.00 | LRAT (0.67) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL15385923 | 0.87 | TSHR (0.57) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL17054698 | 0.87 | HSD17B10 (0.56) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL12930855 | 0.87 | LRAT (0.59) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL14639633 | 0.87 | HSD17B10 (0.56) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL13374328 | 0.87 | LRAT (0.59) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL21454660 | 0.87 | LRAT (0.68) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL17057058 | 0.87 | HSD17B10 (0.56) | LRATMEN1TRPV1HSD17B10TSHR | |
| SCHEMBL12930856 | 0.87 | LRAT (0.59) | LRATMEN1TRPV1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088626-B2 | Chiral selectors for separating enantiomers of a compound | University Joseph Fourier (Grenoble 1) (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20100144045-A1 | CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND | UNIVERISTE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008132340-A2 | CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144045-A1 | CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND | CD2, CD22, CA2 | LRAT 2404/4885MEN1 997/4885TRPV1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.